Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: nakagawa a. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):781-7. doi: 10.1097/MEG.0000000000000105. Eur J Gastroenterol Hepatol. 2014. PMID: 24732752 Clinical Trial.
Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: nakagawa a. Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013. Hepat Mon. 2013. PMID: 24403915 Free PMC article.
Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: nakagawa a. Hepatol Res. 2014 Dec;44(13):1277-85. doi: 10.1111/hepr.12298. Epub 2014 Feb 26. Hepatol Res. 2014. PMID: 24417888
Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C. Nakagawa A, et al. Eur J Gastroenterol Hepatol. 2014 Dec;26(12):1329-34. doi: 10.1097/MEG.0000000000000228. Eur J Gastroenterol Hepatol. 2014. PMID: 25357216
Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
Arai T, Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Itokawa N, Nakagawa A, Okubo T, Aizawa Y, Iwakiri K. Arai T, et al. Among authors: nakagawa a. J Med Virol. 2015 Nov;87(11):1904-12. doi: 10.1002/jmv.24244. Epub 2015 May 11. J Med Virol. 2015. PMID: 25964133
Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients.
Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Kondo C, Itokawa N, Nakagawa A, Arai T, Matsushita Y, Nakatsuka K, Furihata T, Chuganji Y, Matsuzaki Y, Aizawa Y, Iwakiri K. Atsukawa M, et al. Among authors: nakagawa a. BMC Infect Dis. 2015 Aug 19;15:344. doi: 10.1186/s12879-015-1020-y. BMC Infect Dis. 2015. PMID: 26286329 Free PMC article.
1,268 results